ID

38945

Description

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations; ODM derived from: https://clinicaltrials.gov/show/NCT01680328

Link

https://clinicaltrials.gov/show/NCT01680328

Keywords

  1. 11/14/19 11/14/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 14, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes NCT01680328

Eligibility Diabetes NCT01680328

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680328
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent obtained before any trial-related activities.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
type 1 or type 2 diabetes
Description

Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent

Data type

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0011860
daily injection(s) with anti-diabetic drug (insulin or glucagon like peptide-1 (glp-1) analogues) via pen-injector or vial/syringe for more than 6 months
Description

Antidiabetics Injection Daily | Insulin | GLP-1 Analogue | Injection via Pen Injector | Injection via Vial | Injection via Syringe

Data type

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1533685
UMLS CUI [1,3]
C0332173
UMLS CUI [2]
C0021641
UMLS CUI [3]
C3273809
UMLS CUI [4,1]
C1533685
UMLS CUI [4,2]
C1550513
UMLS CUI [4,3]
C4025916
UMLS CUI [5,1]
C1533685
UMLS CUI [5,2]
C1550513
UMLS CUI [5,3]
C0184301
UMLS CUI [6,1]
C1533685
UMLS CUI [6,2]
C1550513
UMLS CUI [6,3]
C0039142
body mass index (bmi) between 18.5 and 30.0 kg/m^2 (both included)
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
caucasians
Description

Caucasians

Data type

boolean

Alias
UMLS CUI [1]
C0043157
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
Description

Hypersensitivity Needle | Other Coding

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0027551
UMLS CUI [2]
C3846158
previous participation in this trial. participation is defined as: screened
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
receipt of any investigational medicinal product that can influence pain perception within 14 days before screening
Description

Investigational New Drugs Influence Pain Perception

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C4054723
UMLS CUI [1,3]
C3714605
injection of more than 40 units of insulin per injection
Description

Injection Insulin Unit Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C1533685
UMLS CUI [1,2]
C0021641
UMLS CUI [1,3]
C0869039
UMLS CUI [1,4]
C1265611
continuous subcutaneous insulin infusion use within the last 6 months
Description

Continuous subcutaneous infusion of insulin

Data type

boolean

Alias
UMLS CUI [1]
C0393124
continuous glucose monitoring use within the last 6 months
Description

Continuous glucose monitoring

Data type

boolean

Alias
UMLS CUI [1]
C4523945
intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
Description

Administration of analgesic | Exception Aspirin Low Dose

Data type

boolean

Alias
UMLS CUI [1]
C0262176
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C2608320
known active or in-active skin disease in the injection area or that may affect pain perception
Description

Dermatologic disorder Injection Area | Dermatologic disorder Affecting Pain Perception

Data type

boolean

Alias
UMLS CUI [1,1]
C0037274
UMLS CUI [1,2]
C1533685
UMLS CUI [1,3]
C0205146
UMLS CUI [2,1]
C0037274
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C3714605
anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. however, not on the day of the injections)
Description

Anticoagulant therapy

Data type

boolean

Alias
UMLS CUI [1]
C0150457

Similar models

Eligibility Diabetes NCT01680328

  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680328
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent obtained before any trial-related activities.
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent
Item
type 1 or type 2 diabetes
boolean
C0011854 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
Antidiabetics Injection Daily | Insulin | GLP-1 Analogue | Injection via Pen Injector | Injection via Vial | Injection via Syringe
Item
daily injection(s) with anti-diabetic drug (insulin or glucagon like peptide-1 (glp-1) analogues) via pen-injector or vial/syringe for more than 6 months
boolean
C0935929 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
C0021641 (UMLS CUI [2])
C3273809 (UMLS CUI [3])
C1533685 (UMLS CUI [4,1])
C1550513 (UMLS CUI [4,2])
C4025916 (UMLS CUI [4,3])
C1533685 (UMLS CUI [5,1])
C1550513 (UMLS CUI [5,2])
C0184301 (UMLS CUI [5,3])
C1533685 (UMLS CUI [6,1])
C1550513 (UMLS CUI [6,2])
C0039142 (UMLS CUI [6,3])
Body mass index
Item
body mass index (bmi) between 18.5 and 30.0 kg/m^2 (both included)
boolean
C1305855 (UMLS CUI [1])
Caucasians
Item
caucasians
boolean
C0043157 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Needle | Other Coding
Item
known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
boolean
C0020517 (UMLS CUI [1,1])
C0027551 (UMLS CUI [1,2])
C3846158 (UMLS CUI [2])
Study Subject Participation Status
Item
previous participation in this trial. participation is defined as: screened
boolean
C2348568 (UMLS CUI [1])
Investigational New Drugs Influence Pain Perception
Item
receipt of any investigational medicinal product that can influence pain perception within 14 days before screening
boolean
C0013230 (UMLS CUI [1,1])
C4054723 (UMLS CUI [1,2])
C3714605 (UMLS CUI [1,3])
Injection Insulin Unit Quantity
Item
injection of more than 40 units of insulin per injection
boolean
C1533685 (UMLS CUI [1,1])
C0021641 (UMLS CUI [1,2])
C0869039 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
Continuous subcutaneous infusion of insulin
Item
continuous subcutaneous insulin infusion use within the last 6 months
boolean
C0393124 (UMLS CUI [1])
Continuous glucose monitoring
Item
continuous glucose monitoring use within the last 6 months
boolean
C4523945 (UMLS CUI [1])
Administration of analgesic | Exception Aspirin Low Dose
Item
intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
boolean
C0262176 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C2608320 (UMLS CUI [2,2])
Dermatologic disorder Injection Area | Dermatologic disorder Affecting Pain Perception
Item
known active or in-active skin disease in the injection area or that may affect pain perception
boolean
C0037274 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
C0205146 (UMLS CUI [1,3])
C0037274 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C3714605 (UMLS CUI [2,3])
Anticoagulant therapy
Item
anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. however, not on the day of the injections)
boolean
C0150457 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial